Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Common Equity (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Common Equity data on record, last reported at $343.4 million in Q4 2025.

  • For Q4 2025, Common Equity rose 52.95% year-over-year to $343.4 million; the TTM value through Dec 2025 reached $343.4 million, up 52.95%, while the annual FY2025 figure was $343.4 million, 52.95% up from the prior year.
  • Common Equity reached $343.4 million in Q4 2025 per TARS's latest filing, up from $335.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $343.4 million in Q4 2025 and bottomed at $147.7 million in Q2 2023.
  • Average Common Equity over 5 years is $228.1 million, with a median of $208.1 million recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 2402.49% in 2021, then crashed 33.31% in 2023.
  • A 5-year view of Common Equity shows it stood at $166.7 million in 2021, then grew by 15.7% to $192.9 million in 2022, then increased by 2.12% to $197.0 million in 2023, then increased by 13.98% to $224.5 million in 2024, then surged by 52.95% to $343.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $343.4 million in Q4 2025, $335.1 million in Q3 2025, and $332.6 million in Q2 2025.